Updated Science on Weight‑Loss Injections: Ozempic, Wegovy, Mounjaro & More
![]() |
GLP‑1 weight-loss injections like Ozempic and Mounjaro can reduce body weight by up to 20%—but not without serious medical risks |
Weight‑loss injections like Ozempic (semaglutide), Wegovy, and Mounjaro (tirzepatide) have revolutionized obesity treatment—but are they safe long-term?
Effectiveness: Clinical Trials vs Real-World Results
A head-to-head clinical trial shows Mounjaro users lost up to 20% of body weight vs 14% for Wegovy.
However, a Cleveland Clinic study of 7,900 patients found average real-world weight loss to be around 6.9% due to inconsistent use and early dropouts.
New Drug: MariTide – Monthly Weight-Loss Shot
A promising new medication, MariTide, offers once-a-month dosing. In a phase 2 trial, it helped participants lose ~16% of body weight in 52 weeks. Learn more via this Health.com article.
Risks and Side Effects
- Pancreatitis: The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) linked over 80 deaths to GLP‑1 drugs. Read the full article on El País.
- Vision loss (NAION): A JAMA Ophthalmology study from Mass General Brigham suggests a 4x increased risk in diabetics.
- Neovascular AMD: A Canadian study reported a doubled risk of retinal damage in semaglutide users.
- Muscle loss: A meta-analysis showed ~25% of weight lost via GLP‑1 drugs is lean muscle.
Safety Guidelines for GLP‑1 Use
- Always begin treatment under the supervision of a qualified healthcare provider.
- Follow dosing instructions; avoid DIY practices like splitting doses.
- Conduct regular follow-up exams, including bloodwork and vision screenings.
- Watch for side effects like abdominal pain, nausea, blurred vision, or fatigue.
- Pair medications with a proper diet, strength training, and medical monitoring.
Expert Opinion
Dr. Mohamed El‑Sayed, internal medicine consultant at Surgical Arts Hospital (Qatar), emphasizes: “GLP‑1 medications are tools—not magic shots. They require structured medical oversight and should never replace a healthy lifestyle.”
These remarks were featured in an Al Jazeera Mubasher interview on the program “With the Doctor” (Ma’a Al‑Hakim).
References & Sources
- The Sun – Mounjaro vs Wegovy Weight Loss Trial
- Health.com – MariTide Monthly Injection Study
- El País – UK Alerts on Pancreatitis Risks
- JAMA Ophthalmology – NAION Risk Study
- ScienceDirect – Neovascular AMD and GLP‑1 Use
- NCBI Meta-analysis – Muscle Loss with GLP‑1s
- Al Jazeera Mubasher – Dr. El-Sayed Interview
Comments
Post a Comment